ATIM-11. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS

Reardon, David A.; Nabors, Burt; Kumthekar, Priya; Badruddoja, Michael; Fink, Karen; Lieberman, Frank S.; Hu, Jethro; Dunbar, Erin; Walbert, Tobias; Schiff, David; Sherman, Jonathan H.; Tran, David; Ashby, Lynn S.; Butowski, Nicholas; Iwamoto, Fábio M.; Moertel, Christopher L.; Schulder, Michael; Chen, Janice; Bullington, J.; Shemesh, Shay; Brooks, Christopher; Goswami, Trishna; Peereboom, David M.

doi:10.1093/neuonc/now212.076

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond targeting of immune checkpoints, other approaches taking advantage of the immune system and the tumor microenvironment are being explored. Dendritic cell and peptide vaccines have entered clinical trials, with promising signs of activity reported in preclinical studies and early phase trials [16,47,48,135,136,[192][193][194][195][196][197]. These encouraging results need further confirmation in the ongoing larger randomized trials.…”

Section: Immunotherapiesmentioning

confidence: 99%

Mechanisms and therapeutic implications of hypermutation in gliomas

Touat

Boynton

et al. 2020

Nature

470

400

View full text Add to dashboard Cite

Je tiens à exprimer mes sincères remerciements à :Monsieur le Professeur Éric Deutsch, de m'avoir fait l'honneur de présider cette thèse. Monsieur le Professeur Ahmed Idbaih et Monsieur le Professeur Keith Ligon, d'avoir pris le temps de diriger et encadrer cette thèse. Monsieur le Docteur Franck Bourdeaut, Madame la Professeure Magali Svrcek, et Monsieur le Professeur Alex Duval, d'avoir pris le temps de juger ce travail. Monsieur le Docteur Franck Bielle, et Monsieur le Professeur Marc Sanson, pour leur participation à ces travaux. Une partie importante de ces travaux a été réalisée au Dana-Farber Cancer Institute et je tiens à remercier ici très sincèrement mes collègues de Boston pour leur amitié et leurs efforts déterminants dans l'obtention de ces résultats, en particulier Keith Ligon pour son accueil au sein de son laboratoire, ses conseils et ses encouragements.

show abstract

Section: Immunotherapiesmentioning

confidence: 99%

Mechanisms and therapeutic implications of hypermutation in gliomas

Touat

Boynton

et al. 2020

Nature

470

400

View full text Add to dashboard Cite

show abstract

“…73 It has been speculated that the results may have been influenced by the patients in the control arm faring better than would be expected of typical control subjects with GBM. 66,73 Reardon et al 74 reported the results of a phase I/II trial of SL-107, a peptide vaccine targeting three tumor antigens— IL-13Rα2, Ephrin A2 (EphA2), and Survivin—in patients with recurrent GBM. Early results showed a partial response in one patient (more than 33 weeks in duration) and stable disease in 15 patients (median duration 8 weeks).…”

Section: Immunotherapy For Gliomamentioning

confidence: 99%

Beyond Alkylating Agents for Gliomas: Quo Vadimus?

Puduvalli

Chaudhary

McClugage

et al. 2017

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

OVERVIEW Recent advances in therapies have yielded notable success in terms of improved survival in several cancers. However, such treatments have failed to improve outcome in patients with gliomas for whom surgery followed by radiation therapy and chemotherapy with alkylating agents remain the standard of care. Genetic and epigenetic studies have helped identify several alterations specific to gliomas. Attempts to target these altered pathways have been unsuccessful due to various factors, including tumor heterogeneity, adaptive resistance of tumor cells, and limitations of access across the blood-brain barrier. Novel therapies that circumvent such limitations have been the focus of intense study and include approaches such as immunotherapy, targeting of signaling hubs and metabolic pathways, and use of biologic agents. Immunotherapeutic approaches including tumor-targeted vaccines, immune checkpoint blockade, antibody-drug conjugates, and chimeric antigen receptor–expressing cell therapies are in various stages of clinical trials. Similarly, identification of key metabolic pathways or converging hubs of signaling pathways that are tumor specific have yielded novel targets for therapy of gliomas. In addition, the failure of conventional therapies against gliomas has led to a growing interest among patients in the use of alternative therapies, which in turn has necessitated developing evidence-based approaches to the application of such therapies in clinical studies. The development of these novel approaches bears potential for providing breakthroughs in treatment of more meaningful and improved outcomes for patients with gliomas.

show abstract

Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?

Kurz

Wen

2018

Curr Treat Options Neurol

View full text Add to dashboard Cite

The results of CheckMate-143 indicated that nivolumab is not superior to bevacizumab in patients with recurrent glioblastoma. A first-in man exploratory study evaluating EGFRvIII-specific CAR T cells for patients with newly diagnosed glioblastoma demonstrated overall safety of CAR T cell therapy and effective target recognition. A pilot study evaluating treatment with adoptively transferred CMV-specific T cells combined with a CMV-specific DC vaccine was found to be safe and resulted in increased polyclonality of CMV-specific T cells in vivo. Despite the success of immunotherapies in many cancers, clinical evidence supporting their efficacy for patients with glioblastoma is still lacking. Nevertheless, the recently published studies provide important proof-of-concept in several areas of immunotherapy research. The careful and critical interpretation of these results will enhance our understanding of the opportunities and challenges of immunotherapies for high-grade gliomas and improve the immunotherapeutic strategies investigated in future clinical trials.

show abstract

ATIM-11. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS

Cited by 6 publications

References 0 publications

Mechanisms and therapeutic implications of hypermutation in gliomas

Mechanisms and therapeutic implications of hypermutation in gliomas

Beyond Alkylating Agents for Gliomas: Quo Vadimus?

Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?

Contact Info

Product

Resources

About